Introducing a new treatment

For adults with moderately to severely active rheumatoid arthritis (RA) who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs.

OlumiantTM, pronounced: [O-loo’-mē-ant]

OlumiantTM (baricitinib) is an oral prescription medicine called a Janus kinase (JAK) inhibitor, indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs. OlumiantTM may be used as mono-therapy or in combination with methotrexate1.

OlumiantTM is a selective and reversible JAK1/JAK2 inhibitor1,2 and is the first once-daily JAK inhibitor approved for RA in India. By inhibiting intracellular JAK1 and JAK2, OlumiantTM directly modulates signaling in a number of cytokines implicated in RA.

References
  1. OlumiantTM (baricitinib) Summary of product characteristics, January 2018
  2. Shi JG, et al. J Clin Pharmacol 2014;54(12):1345-61
Top